PT  - JOURNAL ARTICLE
AU  - Majiya, Hussaini
AU  - Aliyu-Paiko, Mohammed
AU  - Balogu, Vincent T
AU  - Musa, Dickson A
AU  - Salihu, Ibrahim M
AU  - Kawu, Abdullahi A
AU  - Bashir, Yakubu I
AU  - Sani, Aishat A
AU  - John, Baba
AU  - Muhammad, Amina T
AU  - Jibril, Fatima L
AU  - Bala, Ezekiel
AU  - Obaje, Nuhu G
AU  - Aliyu, Yahaya B.
AU  - Muhammad, Ramatu G
AU  - Mohammed, Hadiza
AU  - Gimba, Usman N
AU  - Uthman, Abduljelili
AU  - Liman, Hadiza M
AU  - Sule, Alfa A
AU  - Joseph, Kolo J
AU  - Makusidi, Mohammed M
AU  - Isah, Mohammed D
AU  - Abdullahi, Ibrahim
AU  - Ndagi, Umar
AU  - Waziri, Bala
AU  - Bisallah, Chindo I
AU  - Dadi-Mamud, Naomi J
AU  - Ibrahim, Kolo
AU  - Adamu, Abu Kasim
TI  - Seroprevalence of SARS-CoV-2 in Niger State: A Pilot Cross Sectional Study
AID  - 10.1101/2020.08.04.20168112
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.08.04.20168112
4099  - http://medrxiv.org/content/early/2021/06/20/2020.08.04.20168112.short
4100  - http://medrxiv.org/content/early/2021/06/20/2020.08.04.20168112.full
AB  - Background Coronavirus Disease 2019 (COVID-19) Pandemic caused by SARS-CoV-2 is ongoing causing human and socioeconomic losses.Objective To know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the SARS-CoV-2 seroprevalence, patterns, dynamics, and risk factors in the state.Methods A cross sectional study design and Clustered-Stratified-Random sampling strategy were used to select 185 test participants across the state. SARS-CoV-2 IgG and IgM Rapid Test Kits (Colloidal gold immunochromatography lateral flow system) were used to determine the presence or absence of the antibodies to the virus in the blood of sampled participants across Niger State as from 26th June 2020 to 30th June 2020. The test kits were validated using the blood samples of some of the Nigeria Center for Disease Control (NCDC) confirmed positive and negative COVID-19 cases in the State. SARS-CoV-2 IgG and IgM Test results were entered into the EPIINFO questionnaire administered simultaneously with each test. EPIINFO was then used for to calculate arithmetic mean and percentage, odd ratio, chi-square, and regression at 95% Confidence Interval of the data generated.Results The seroprevalence of SARS-CoV-2 in Niger State was found to be 25.41% and 2.16% for the positive IgG and IgM respectively. Seroprevalence among age groups, gender and by occupation varied widely. COVID-19 asymptomatic rate in the state was found to be 46.81%. The risk analyses showed that the chances of infection are almost the same for both urban and rural dwellers in the state. However, health care workers, those that experienced flu-like symptoms and those that have had contact with person (s) that travelled out of Nigeria in the last six (6) months (February -June 2020) are twice (2 times) at risk of being infected with the virus. More than half (54.59%) of the participants in this study did not practice social distancing at any time since the pandemic started. Discussions about knowledge, practice and attitude of the participants are included.Conclusion The observed Niger State SARS-CoV-2 seroprevalence and infection patterns means that the virus is widely spread, far more SARS CoV-2 infections occurred than the reported cases and high asymptomatic COVID-19 across the state.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Ibrahim Badamasi Babangida University, Lapai, Niger State, Nigeria.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee, Niger Sate Ministry of Health, Minna, NigeriaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available